87 related articles for article (PubMed ID: 38699288)
1. Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cells.
Cappabianca D; Li J; Zheng Y; Tran C; Kasparek K; Mendez P; Thu R; Maures T; Capitini CM; Deans R; Saha K
Front Bioeng Biotechnol; 2024; 12():1379900. PubMed ID: 38882639
[TBL] [Abstract][Full Text] [Related]
2. Building a novel TRUCK by harnessing the endogenous IFN-gamma promoter for cytokine expression.
Ma L; Zhang K; Xu J; Wang J; Jiang T; Du X; Zhang J; Huang J; Ren F; Liu D; Xue W; Kan D; Yao M; Liang Y; Jason-Sun H
Mol Ther; 2024 Jun; ():. PubMed ID: 38879754
[TBL] [Abstract][Full Text] [Related]
3. A high-density microfluidic bioreactor for the automated manufacturing of CAR T cells.
Sin WX; Jagannathan NS; Teo DBL; Kairi F; Fong SY; Tan JHL; Sandikin D; Cheung KW; Luah YH; Wu X; Raymond JJ; Lim FLWI; Lee YH; Seng MS; Soh SY; Chen Q; Ram RJ; Tucker-Kellogg L; Birnbaum ME
Nat Biomed Eng; 2024 Jun; ():. PubMed ID: 38834752
[TBL] [Abstract][Full Text] [Related]
4. A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies.
Razeghian E; Nasution MKM; Rahman HS; Gardanova ZR; Abdelbasset WK; Aravindhan S; Bokov DO; Suksatan W; Nakhaei P; Shariatzadeh S; Marofi F; Yazdanifar M; Shamlou S; Motavalli R; Khiavi FM
Stem Cell Res Ther; 2021 Jul; 12(1):428. PubMed ID: 34321099
[TBL] [Abstract][Full Text] [Related]
5. Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy.
Naeem M; Hazafa A; Bano N; Ali R; Farooq M; Razak SIA; Lee TY; Devaraj S
Life Sci; 2023 Mar; 316():121409. PubMed ID: 36681183
[TBL] [Abstract][Full Text] [Related]
6. Metabolic priming of GD2
Cappabianca D; Pham D; Forsberg MH; Bugel M; Tommasi A; Lauer A; Vidugiriene J; Hrdlicka B; McHale A; Sodji QH; Skala MC; Capitini CM; Saha K
Mol Ther Methods Clin Dev; 2024 Jun; 32(2):101249. PubMed ID: 38699288
[TBL] [Abstract][Full Text] [Related]
7. Metabolic priming of GD2
Cappabianca D; Pham D; Forsberg MH; Bugel M; Tommasi A; Lauer A; Vidugiriene J; Hrdlicka B; McHale A; Sodji Q; Skala MC; Capitini CM; Saha K
bioRxiv; 2024 Mar; ():. PubMed ID: 38562720
[TBL] [Abstract][Full Text] [Related]
8. Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression.
Mueller KP; Piscopo NJ; Forsberg MH; Saraspe LA; Das A; Russell B; Smerchansky M; Cappabianca D; Shi L; Shankar K; Sarko L; Khajanchi N; La Vonne Denne N; Ramamurthy A; Ali A; Lazzarotto CR; Tsai SQ; Capitini CM; Saha K
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36382633
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological interventions enhance virus-free generation of
Kath J; Du W; Pruene A; Braun T; Thommandru B; Turk R; Sturgeon ML; Kurgan GL; Amini L; Stein M; Zittel T; Martini S; Ostendorf L; Wilhelm A; Akyüz L; Rehm A; Höpken UE; Pruß A; Künkele A; Jacobi AM; Volk HD; Schmueck-Henneresse M; Stripecke R; Reinke P; Wagner DL
Mol Ther Methods Clin Dev; 2022 Jun; 25():311-330. PubMed ID: 35573047
[TBL] [Abstract][Full Text] [Related]
10. Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing.
Balke-Want H; Keerthi V; Gkitsas N; Mancini AG; Kurgan GL; Fowler C; Xu P; Liu X; Asano K; Patel S; Fisher CJ; Brown AK; Tunuguntla RH; Patel S; Sotillo E; Mackall CL; Feldman SA
Mol Cancer; 2023 Jun; 22(1):100. PubMed ID: 37365642
[TBL] [Abstract][Full Text] [Related]
11. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
Gargett T; Truong N; Ebert LM; Yu W; Brown MP
Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
[TBL] [Abstract][Full Text] [Related]
12. Cas9-induced targeted integration of large DNA payloads in primary human T cells via homology-mediated end-joining DNA repair.
Webber BR; Johnson MJ; Skeate JG; Slipek NJ; Lahr WS; DeFeo AP; Mills LJ; Qiu X; Rathmann B; Diers MD; Wick B; Henley T; Choudhry M; Starr TK; McIvor RS; Moriarity BS
Nat Biomed Eng; 2023 Dec; ():. PubMed ID: 38092857
[TBL] [Abstract][Full Text] [Related]
13. Regulation of CD8
Chen Y; Xu Z; Sun H; Ouyang X; Han Y; Yu H; Wu N; Xie Y; Su B
Cell Mol Immunol; 2023 Sep; 20(9):1023-1039. PubMed ID: 37582972
[TBL] [Abstract][Full Text] [Related]
14. Improving cell and gene therapy safety and performance using next-generation Nanoplasmid vectors.
Williams JA; Paez PA
Mol Ther Nucleic Acids; 2023 Jun; 32():494-503. PubMed ID: 37346980
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of CRISPR-based non-viral
Hu Y; Zu C; Zhang M; Wei G; Li W; Fu S; Hong R; Zhou L; Wu W; Cui J; Wang D; Du B; Liu M; Zhang J; Huang H
EClinicalMedicine; 2023 Jun; 60():102010. PubMed ID: 37251628
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
